Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

Milestones Include Top-Tier 3-Year Accreditations from OASAS and The Joint Commission, Staff Growth to Over 20 ...

All FDA warnings are at the end of this fact sheet. Please consult them before taking this medication. What Is Xanomeline and Trospium and What Does It Treat? Xanomeline and trospium is a medication ...

Shares of Indivior (NASDAQ:INDV) climbed 4.5% in U.S. premarket trading on Thursday after the company issued fiscal 2026 ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE- Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

Mental health conditions are complex, and research is critical to helping us understand more about them and how they affect people. There are many different types of research and ways for the public ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

The mid-point of Indivior’s FY26 guidance suggests 3% upside to consensus group sales estimates and 3% upside to Sublocade sales forecasts. The company’s adjusted EBITDA guidance was particularly ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

Following a successful launch in 2024, The Centers announced the expansion of its Walk-in Medication Assisted Treatment Clinic, or WinMAT, earlier this year, with a second site opening at its ...

Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 ...

Oregon-based Stonepine Capital Management reduced its Indivior stake by 250,000 shares in the third quarter. The overall position value fell by about $2.75 million from the previous period. As of ...